Our Story
JY BioMedical was established in 2016, focusing on the development of functional health supplements. In 2020, following the outbreak of the COVID-19 pandemic, we gradually transformed into a biotechnology and pharmaceutical research and development firm. This shift demonstrates our flexibility and adaptability in the face of challenges. By making this critical transition, we have further enhanced expertise and influence in the biomedical and pharmaceutical sectors. Such a transformation not only enables the development of new biotechnological products but also opens up more market opportunities and growth potential.
Innovation
JY BioMedical specializes in personalized medicine, leveraging dendritic cells (DCs) and MSC-derived exosomes to enhance the body’s immune response against cancer. The company’s DC cancer vaccines are developed using specialized antigen-presenting cells, which directly or indirectly train T cells to recognize and attack tumor cells. This approach ensures high specificity and efficacy in targeting various cancer types, with a low risk of rejection due to the autologous nature of the treatment.
In addition to DC vaccines, JY BioMedical’s Gamma-Delta T cell therapies utilize the unique properties of these immune cells to offer broad-spectrum anti-tumor activity. These therapies are designed to recognize and kill a wide range of malignant cells, making them a versatile and powerful tool in cancer treatment. The company’s MSC and MSC-derived exosome products further contribute to regenerative medicine by promoting tissue repair, modulating immune responses, and offering potential treatments for a variety of inflammatory and degenerative conditions.
Moreover, JY BioMedical is advancing its cancer treatment portfolio with the development of an Antibody Drug Conjugate (Anti-CEACAM6 Heavy Chain Ab). This targeted therapy combines an antibody that specifically binds to the CEACAM6 protein, commonly overexpressed in several types of tumors, with a potent cytotoxic agent. By delivering the drug directly to cancer cells, the Anti-CEACAM6 conjugate enhances treatment efficacy while minimizing damage to healthy tissues, thereby representing a significant advancement in precision oncology.
Research & Development
JY BioMedical’s commitment to innovation is reflected in its robust R&D pipeline, which includes preclinical and clinical trials across multiple therapeutic areas. The company is actively exploring the potential of exosome-based therapies for ocular diseases, such as dry eye syndrome and glaucoma, as well as investigating the applications of MSC technologies in wound care and skin regeneration.
Our Vision & Commitment
At JY BioMedical, the mission is to advance the frontiers of medicine through pioneering research and the development of transformative therapies. The company’s vision is to improve patient outcomes and quality of life by providing accessible, effective, and innovative medical solutions. With a team of dedicated scientists, clinicians, and industry experts, JY BioMedical is committed to making a difference in the lives of patients worldwide.
JY BioMedical stands at the forefront of biotechnology innovation, offering cutting-edge therapies that address unmet medical needs. As a trusted partner in healthcare, the company continues to push the boundaries of science to deliver breakthrough treatments that have the potential to transform patient care. Whether through cancer vaccines, T cell therapies, or regenerative medicine, JY BioMedical is dedicated to leading the way in medical innovation.
